Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › lamivudine

lamivudine

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of lamivudine

28 trials tracked of lamivudine: 15 in phase 3 or 4 and 6 with published results. The most-cited published study has 6953 citations.

28Trials tracked
15Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 4 Phase 3 11 Phase 2 9 Phase 1 1 Other / NA 3
  1. Phase 3 Preventing Sexual Transmission of HIV With Anti-HIV Drugs Completed · 6,953 cited
  2. Phase 3 Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth Completed · 1,421 cited
  3. Phase 3 Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure Completed · 85 cited
  4. Phase 3 Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women Completed · 51 cited
  5. Phase 3 Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years Completed · 43 cited
  6. Phase 4 A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers Completed · 35 cited
Show 22 more trials
  1. Phase 4 Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir Completed
  2. Phase 4 A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection Completed
  3. Phase 4 Antiretroviral Therapy for Advanced HIV Disease in South Africa Completed
  4. Phase 3 A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase Completed
  5. Phase 3 Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM Completed
  6. Phase 3 Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus Completed
  7. Phase 3 Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis Completed
  8. Phase 3 Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B Completed
  9. Phase 3 Study of Options for Second-Line Effective Combination Therapy (SELECT) Completed
  10. Phase 2 Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease Completed
  11. Phase 2 Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials Completed
  12. Phase 2 Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients Completed
  13. Phase 2 A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years Completed
  14. Phase 2 Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV Completed
  15. Phase 2 A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Completed
  16. Phase 2 A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents Completed
  17. Phase 2 Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) Completed
  18. Phase 2 Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants Completed
  19. Phase 1 Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine Completed
  20. N/A Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities Completed
  21. N/A Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia Completed
  22. N/A The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation Completed

Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bictegravir/emtricitabine/tenofovir alafenamide shows favorable lipid and renal changes versus other regimens in treatment-experienced HIV-1 patients
Infectious Disease Sys. Review
Bictegravir/emtricitabine/tenofovir alafenamide shows favorable lipid and renal changes versus other regimens in treatment-experienced HIV-1 patients New review shows a specific HIV drug combo may improve cholesterol and kidney health
This systematic literature review and network meta-analysis evaluates bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) against othe…
A large review found that a specific HIV drug combination improved cholesterol and kidney function compared to other common treatments for e…
Jun 4, 2026
Preplanned subanalysis shows comparable viral suppression rates for two dolutegravir-based regimens in antiretroviral-naive people with HIV at week 48
Infectious Disease RCT
Preplanned subanalysis shows comparable viral suppression rates for two dolutegravir-based regimens in antiretroviral-naive people with HIV at week 48 New HIV drug combo shows similar virus control to standard care in people with resistance markers
A preplanned subanalysis of a phase IV study compared dolutegravir plus lamivudine against dolutegravir plus tenofovir disoproxil fumarate w…
A specific HIV drug mix controlled the virus just as well as a standard mix in people with certain resistance markers, offering a potential …
Jun 1, 2026
HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy
Infectious Disease RCT
HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy HIV drug resistance patterns vary by region and prior treatment history
This substudy examined HIV-1 drug resistance mutations in people failing first-line therapy across 14 countries.
HIV drug resistance varies by region and prior treatment. Subtype C dominates, but resistance to common drugs is high. This matters for choo…
May 1, 2026
Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months
Drug Pipeline Cohort
Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months Switching HIV drugs showed similar metabolic changes over two years in this real-world study
This retrospective real-world study evaluated 326 virologically suppressed persons with HIV (PLWH) switching from efavirenz/tenofovir disopr…
Switching HIV drugs caused similar weight gain and metabolic shifts over two years, meaning lifestyle factors matter more than the specific …
Frontiers Apr 18, 2026
Nevirapine plus lamivudine and zidovudine improved lymphocyte counts and reduced adverse effects versus efavirenz in HIV patients
Infectious Disease RCT
Nevirapine plus lamivudine and zidovudine improved lymphocyte counts and reduced adverse effects versus efavirenz in HIV patients New HIV drug combo showed fewer side effects and better immune markers in small trial
This randomized controlled trial enrolled 100 patients with HIV/AIDS in a hospital setting.
A new HIV drug combo boosted immune cells and caused fewer side effects than the standard alternative in a recent trial.
NEJM Apr 14, 2026